If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Income 1 Regulatory News (MIG1)

Share Price Information for Maven Income 1 (MIG1)

Share Price is delayed by 15 minutes
Get Live Data
33.80    0.00 (0.00%)
Bid:
32.80
Ask:
34.80
Spread: 2.00 (6.098%)
Market Cap: £70.16m
MIG1 Live PriceLast checked at - London Stock Exchange

Intraday Maven Income 1 Share Chart

Issue of Equity

3 Mar 2023 09:47

RNS Number : 8524R
Maven Income & Growth VCT PLC
03 March 2023
 

Maven Income and Growth VCT PLC (the Company)

 

Issue of Equity

 

On 7 October 2022, the Company launched an offer for subscription for new ordinary shares of 10p each (Ordinary Shares) to raise up to £10 million (the Offer).

 

Pursuant to the Offer, a total of £3,882,067 of valid applications were received in the period from 7 October 2022 up to close of business on 28 February 2023. In respect of the 2022/2023 tax year, £3,607,948 of valid applications were received and, as a result, the Company has issued and allotted 8,130,478 new Ordinary Shares on 3 March 2023. In accordance with the allotment formula set out in the prospectus for the Offer, the offer prices at which the shares were issued were in the range of 43.75p to 45.57p per Ordinary Share and, as a result, the number of Ordinary Shares now in issue is 142,131,075. Therefore, the total number of voting rights in the Company is 142,131,075.

 

In respect of this allotment, an application will be made by the Company to the FCA and to the London Stock Exchange for the new Ordinary Shares so issued to be admitted to the Official List and to trading on the London Stock Exchange's main market for listed securities. It is expected that the admission of the new Ordinary Shares will become effective and dealings will commence on or around 8 March 2023.

 

The above statement of Voting Capital may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

The Board of the Company intends that a final allotment in respect of applications for the 2022/2023 tax year will take place on or before 5 April 2023. It is also intended that an allotment in respect of applications for the 2023/2024 tax year will take place on or before 31 May 2023, unless the Offer is fully subscribed by an earlier date or extended, at the Board's discretion, to a date up to and including 6 October 2023.

 

For further information, please contact:

 

Maven Capital Partners UK LLP

Telephone: 0141 306 7400

E-mail: enquiries@mavencp.com

 

Maven Capital Partners UK LLP

Secretary

 

3 March 2023

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEKXLBBXXLZBBZ
Date   Source Headline
6th Jul 20234:01 pmRNSStatement re Intended Offers for Subscription
6th Jul 20233:37 pmRNSNet Asset Value
6th Jul 20231:06 pmRNSResult of AGM
7th Jun 20234:21 pmRNSAnnual Financial Report
2nd Jun 20239:39 amRNSIssue of Equity
1st Jun 202312:18 pmRNSNet Asset Value(s)
26th May 20233:53 pmRNSTransaction in Own Shares
24th May 202310:52 amRNSUnaudited NAV and Proposed Final Dividend
27th Apr 20231:04 pmRNSIssue of Supplementary Prospectus
5th Apr 202312:33 pmRNSDirector/PDMR Shareholding
5th Apr 202312:26 pmRNSIssue of Equity
29th Mar 20232:19 pmRNSIssue of Supplementary Prospectus
3rd Mar 202310:37 amRNSDirector/PDMR Shareholding
3rd Mar 202310:35 amRNSDirector/PDMR Shareholding
3rd Mar 202310:35 amRNSDirector/PDMR Shareholding
3rd Mar 20239:47 amRNSIssue of Equity
21st Feb 20234:39 pmRNSTransaction in Own Shares
6th Feb 20234:23 pmRNSNet Asset Value(s)
2nd Dec 20229:30 amRNSIssue of Equity
25th Nov 202212:36 pmRNSStatement re Dividend Investment Scheme
9th Nov 20222:34 pmRNSResult of General Meeting
4th Nov 202211:15 amRNSHalf-year Report
26th Oct 20223:50 pmRNSTransaction in Own Shares
14th Oct 20223:33 pmRNSNet Asset Value and Interim Dividend
7th Oct 20224:28 pmRNSPublication of a Prospectus
4th Oct 20223:30 pmRNSChange of Auditor
5th Aug 20224:39 pmRNSTransaction in Own Shares
15th Jul 202211:08 amRNSIssue of Equity
11th Jul 20223:12 pmRNSStatement re Dividend Investment Scheme
8th Jul 20223:28 pmRNSStatement re Joint Offers for Subscription
8th Jul 20222:36 pmRNSNet Asset Value(s)
7th Jul 20222:34 pmRNSResult of AGM
8th Jun 20222:12 pmRNSAnnual Financial Report
29th Apr 20222:28 pmRNSTransaction in Own Shares
27th Apr 20224:04 pmRNSTransaction in Own Shares
21st Apr 202211:22 amRNSStatement re NAV and Proposed Final Dividend
25th Jan 20224:04 pmRNSTransaction in Own Shares
21st Jan 20223:15 pmRNSNet Asset Value(s)
3rd Dec 20219:48 amRNSIssue of Equity
26th Nov 20219:53 amRNSStatement re Dividend Investment Scheme
12th Nov 20214:31 pmRNSHalf-year Report
11th Nov 20214:23 pmRNSTransaction in Own Shares
9th Nov 20211:33 pmRNSTransaction in Own Shares
27th Oct 20214:44 pmRNSNet Asset Value and Interim Dividend
20th Sep 20214:57 pmRNSStatement re Change of Registrar
16th Jul 202110:04 amRNSIssue of Equity
12th Jul 20214:28 pmRNSStatement re Dividend Investment Scheme
7th Jul 20213:32 pmRNSNet Asset Value(s)
7th Jul 202112:37 pmRNSResult of AGM
4th Jun 20214:16 pmRNSAnnual Financial Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.